[
  {
    "ts": null,
    "headline": "The Take On Tyra Biosciences",
    "summary": "Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg.",
    "url": "https://finnhub.io/api/news?id=1989fef2977fc61d12075dedb7f7a4cf77cf88bac5a05fa7e2f102baf15ad002",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734455615,
      "headline": "The Take On Tyra Biosciences",
      "id": 132030976,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg.",
      "url": "https://finnhub.io/api/news?id=1989fef2977fc61d12075dedb7f7a4cf77cf88bac5a05fa7e2f102baf15ad002"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson stock outperforms competitors on strong trading day",
    "summary": "Johnson & Johnson stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=a72455f939d160e5718209532ab171a1278fe4645ef80a44250ebd2119ad6605",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734453060,
      "headline": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "id": 132064823,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=a72455f939d160e5718209532ab171a1278fe4645ef80a44250ebd2119ad6605"
    }
  },
  {
    "ts": null,
    "headline": "FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC",
    "summary": "The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.",
    "url": "https://finnhub.io/api/news?id=deab0c819be10ba50c047351dae1a927aac5901c37099ae92750e03c2e968a06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734441660,
      "headline": "FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC",
      "id": 132031116,
      "image": "https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.",
      "url": "https://finnhub.io/api/news?id=deab0c819be10ba50c047351dae1a927aac5901c37099ae92750e03c2e968a06"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) Has A Pretty Healthy Balance Sheet",
    "summary": "David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...",
    "url": "https://finnhub.io/api/news?id=f3dedc4f888cb1f0a8507aa9edd80f6d944aa54851eccb6bccd06618e242e45c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734436827,
      "headline": "Johnson & Johnson (NYSE:JNJ) Has A Pretty Healthy Balance Sheet",
      "id": 132023713,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/2eedc463aef15274c4887c130e30e298",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...",
      "url": "https://finnhub.io/api/news?id=f3dedc4f888cb1f0a8507aa9edd80f6d944aa54851eccb6bccd06618e242e45c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - Update on U.S. regulatory review of subcutaneous amivantamab",
    "summary": "RARITAN - Johnson & Johnson today announced the U.S. Food and Drug Administration has issued a Complete Response Letter for the Biologics License Application for a fixed combination of amivantamab...",
    "url": "https://finnhub.io/api/news?id=29900637138e336b2d4a070076e1dc28cee66d2563b629e460ff78f292ad3c5c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734429648,
      "headline": "Johnson & Johnson - Update on U.S. regulatory review of subcutaneous amivantamab",
      "id": 132025166,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "RARITAN - Johnson & Johnson today announced the U.S. Food and Drug Administration has issued a Complete Response Letter for the Biologics License Application for a fixed combination of amivantamab...",
      "url": "https://finnhub.io/api/news?id=29900637138e336b2d4a070076e1dc28cee66d2563b629e460ff78f292ad3c5c"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson submits application seeking U.S. FDA approval of SIMPONI for the treatment of pediatric ulcerative colitis",
    "summary": "HORHSAM - Johnson & Johnson today announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking expanded approval of SIMPONI for the...",
    "url": "https://finnhub.io/api/news?id=c4f8e9eab1189485b8e5b27a2fbafd5ae55243c0836e0d9f3151fa8b26aebe9f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734429648,
      "headline": "Johnson & Johnson submits application seeking U.S. FDA approval of SIMPONI for the treatment of pediatric ulcerative colitis",
      "id": 132025165,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "HORHSAM - Johnson & Johnson today announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking expanded approval of SIMPONI for the...",
      "url": "https://finnhub.io/api/news?id=c4f8e9eab1189485b8e5b27a2fbafd5ae55243c0836e0d9f3151fa8b26aebe9f"
    }
  },
  {
    "ts": null,
    "headline": "J&J: FDA delays approval of Rybrevant in NSCLC",
    "summary": "Johnson & Johnson announces that it has received a Complete Response Letter from the U.S. Food and Drug Administration following its Biologics License Application for the subcutaneous fixed...",
    "url": "https://finnhub.io/api/news?id=d1c2b7f0b1db837283bb8370cfcd44d961d5a80894c5ced070c7ce6f22701b40",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734409398,
      "headline": "J&J: FDA delays approval of Rybrevant in NSCLC",
      "id": 132022103,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces that it has received a Complete Response Letter from the U.S. Food and Drug Administration following its Biologics License Application for the subcutaneous fixed...",
      "url": "https://finnhub.io/api/news?id=d1c2b7f0b1db837283bb8370cfcd44d961d5a80894c5ced070c7ce6f22701b40"
    }
  }
]